Astrana Health (NASDAQ:ASTH) Hits New 1-Year Low After Analyst Downgrade

Astrana Health, Inc. (NASDAQ:ASTH) shares reached a new 52-week low on Monday after Truist Financial lowered their price target on the stock from $59.00 to $50.00. Truist Financial currently has a buy rating on the stock. Astrana Health traded as low as $29.08 and last traded at $29.42, with a volume of 13470 shares traded. The stock had previously closed at $29.48.

Other equities analysts have also issued research reports about the company. Robert W. Baird lifted their price target on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. BTIG Research upped their price objective on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. KeyCorp initiated coverage on shares of Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating on the stock. TD Cowen began coverage on shares of Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 price target for the company. Finally, Macquarie raised Astrana Health to a “hold” rating in a report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Astrana Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $63.67.

Hedge Funds Weigh In On Astrana Health

A number of hedge funds have recently bought and sold shares of ASTH. State Street Corp bought a new position in shares of Astrana Health during the 3rd quarter worth approximately $91,966,000. Geode Capital Management LLC bought a new position in Astrana Health during the third quarter worth $58,995,000. FMR LLC bought a new position in Astrana Health during the third quarter worth $48,413,000. SteelPeak Wealth LLC acquired a new stake in Astrana Health in the third quarter worth $39,398,000. Finally, Loomis Sayles & Co. L P acquired a new stake in Astrana Health in the third quarter worth $30,251,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Trading Up 3.0 %

The stock has a market capitalization of $1.75 billion, a P/E ratio of 23.99, a P/E/G ratio of 1.80 and a beta of 1.20. The firm’s 50 day simple moving average is $39.07 and its two-hundred day simple moving average is $46.97. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The business had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. During the same period in the prior year, the business earned $0.47 EPS. As a group, analysts forecast that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.